Comparing NantHealth (NH) & Its Peers
NantHealth (NASDAQ: NH) is one of 20 public companies in the “Medical Software & Technology Services” industry, but how does it contrast to its rivals? We will compare NantHealth to similar businesses based on the strength of its dividends, valuation, risk, profitability, earnings, analyst recommendations and institutional ownership.
Insider & Institutional Ownership
7.1% of NantHealth shares are owned by institutional investors. Comparatively, 62.9% of shares of all “Medical Software & Technology Services” companies are owned by institutional investors. 58.0% of NantHealth shares are owned by company insiders. Comparatively, 26.5% of shares of all “Medical Software & Technology Services” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This table compares NantHealth and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|NantHealth||$100.38 million||-$184.10 million||-1.81|
|NantHealth Competitors||$413.57 million||-$24.55 million||19,220.31|
NantHealth’s rivals have higher revenue and earnings than NantHealth. NantHealth is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
NantHealth has a beta of -1.49, indicating that its stock price is 249% less volatile than the S&P 500. Comparatively, NantHealth’s rivals have a beta of 1.17, indicating that their average stock price is 17% more volatile than the S&P 500.
This is a breakdown of recent ratings and price targets for NantHealth and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
NantHealth currently has a consensus target price of $9.00, suggesting a potential upside of 179.50%. As a group, “Medical Software & Technology Services” companies have a potential downside of 96.47%. Given NantHealth’s stronger consensus rating and higher probable upside, equities research analysts clearly believe NantHealth is more favorable than its rivals.
This table compares NantHealth and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
NantHealth rivals beat NantHealth on 8 of the 12 factors compared.
NantHealth, Inc. is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples. The Company also offers Nant Operating System (NantOS) and NantOS applications to healthcare providers and payors, self-insured employers and biopharmaceutical companies. It offers CLINICS, an integrated solution that includes GPS Cancer, NantOS and the NantOS applications. The CLINICS solution includes System Infrastructure, Knowledge Platform, Provider Platform and Payor Platform.
Receive News & Ratings for NantHealth Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc. and related companies with MarketBeat.com's FREE daily email newsletter.